An Update on JAK Inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Signal Transduction

Background:

• Janus kinases (JAKs) are key mediators of inflammatory and autoimmune diseases via the JAK/STAT pathway.
• The JAK2 V617F mutation is linked to myeloproliferative neoplasms, driving research into JAK inhibitors.
• Several small molecule JAK inhibitors have reached the market, primarily as pyrrolo[2,3-d]pyrimidine derivatives.

Purpose of the Study:

• To review representative small molecule JAK inhibitors published between 2013-2017.
• To classify inhibitors based on chemical structure, structure-activity relationships (SAR), selectivity, and biological activity.
• To provide context by briefly mentioning earlier compounds that entered clinical trials.

Main Methods:

• Literature and patent search for JAK inhibitors published from 2013 to 2017.
• Classification of identified compounds by chemical scaffold.
• Analysis of SAR, selectivity, and biological activity data for representative inhibitors.

Main Results:

• Numerous JAK inhibitors with diverse heterocyclic scaffolds have been reported.
• Structure-activity relationship studies reveal key features for selective or multi-JAK inhibition.
• Several novel compounds are under clinical evaluation, indicating promising therapeutic potential.

Conclusions:

• The field of JAK inhibitor discovery is rapidly advancing with diverse chemical entities.
• Understanding SAR is critical for developing potent and selective inhibitors for various diseases.
• Continued research into novel scaffolds holds promise for future therapeutic breakthroughs.